AI's Bottleneck In Clinical Trials Moved, And Most People Missed It

By John Paul (JP) Lee, COO, AG Mednet

At first glance, it would seem as if AI has completely solved the drug development puzzle by compressing discovery timelines. But finding a viable molecule is no longer the industry’s primary bottleneck. As generative models flood the pipeline with promising candidates, the constraint has shifted downstream into trial operations, data reconciliation, and site coordination. The real challenge is no longer speed, but the models' orchestration and governance. A rapid data harmonization process is completely worthless to a sponsor if it cannot survive the strict scrutiny of regulatory bodies like the FDA. To deploy agentic AI within a heavily regulated, GxP-compliant environment, every single output must be fully reproducible, transparent, and auditable. Explore why organizations must pivot their focus from pure model speed to rigorous compliance frameworks, and learn how to navigate this next phase of clinical transformation by making AI's velocity completely auditable.